Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Radek Pudil*, Christian Mueller, Jelena Čelutkienė, Peter A. Henriksen, Dan Lenihan, Susan Dent, Ana Barac, Susanna Stanway, Javid Moslehi, Thomas M. Suter, Bonnie Ky, Martin Štěrba, Daniela Cardinale, Alain Cohen-Solal, Carlo Gabriele Tocchetti, Dimitrios Farmakis, Jutta Bergler-Klein, Markus S. Anker, Stephan Von Haehling, Yury BelenkovZaza Iakobishvili, Christoph Maack, Fortunato Ciardiello, Frank Ruschitzka, Andrew J.S. Coats, Petar Seferovic, Mitja Lainscak, Massimo F. Piepoli, Ovidiu Chioncel, Jereon Bax, Jean Sebastien Hulot, Hadi Skouri, Eva Simona Hägler-Laube, Riccardo Asteggiano, Teresa Lopez Fernandez, Rudolf A. de Boer, Alexander R. Lyon*

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

237 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology'. Together they form a unique fingerprint.

Medicine and Dentistry